Loading...
•
Jun 30, 2021
Allovir Q2 2021 Earnings Report
Reported financial results for the second quarter ended June 30, 2021.
Key Takeaways
AlloVir reported financial results for Q2 2021. The net loss was $37.6 million, or $0.60 per share. As of June 30, 2021, AlloVir had cash, cash equivalents, and marketable securities of $313.3 million.
Posoleucel proof-of-concept studies in multi-virus prevention in stem cell transplant patients and BK viremia in kidney transplant patients continue to progress with initial data expected 4Q21.
Posoleucel Phase 3 pivotal trial in virus-associated hemorrhagic cystitis continues to progress enrollment.
ALVR106 proof-of-concept study in respiratory syncytial virus, influenza, human metapneumovirus, and parainfluenza expected to initiate in 2H21.
Dr. Diana Brainard officially commenced her role as Chief Executive Officer as of May 17 this year.
Forward Guidance
AlloVir is advancing multiple mid- and late-stage clinical trials across its product portfolio.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...